維康藥業(300878.SZ):部分募投項目延期
格隆匯 2 月 3日丨維康藥業(300878.SZ)公佈,公司於2021年2月2日召開第二屆董事會第十六次會議、第二屆監事會第八次會議,審議通過了《關於部分募集資金投資項目延期的議案》。
經審議,董事會認為公司根據募集資金投資項目的實際建設情況和投資進度,採取審慎的態度調整募集資金投資項目“醫藥大健康產業園一期項目(中藥飲片及中藥提取、研發中心、倉儲中心)”、“營銷網絡中心建設項目”達到預定可使用狀態的日期,符合募集資金投資項目的實際情況和公司的發展規劃,不存在改變或變相改變募集資金投向和其他損害股東利益的情形。同意公司將上述募集資金投資項目達到預定可使用狀態的日期延長至2021年12月31日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.